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Abstract
Vasoactive intestinal peptide (VIP), which is present with ace-
tylcholine in parasympathetic nerve fibers, may have impor-
tant regulatory functions in mucous membranes. The potential
roles for VIP in human nasal mucosa were studied using an
integrated approach. The VIP content of human nasal mucosa
was determined to be 2.84±0.47 pmol/g wet weight (n = 8) by
RIA. VIP-immunoreactive nerve fibers were found to be most
concentrated in submucosal glands adjacent to serous and
mucous cells. 125I-VIP binding sites were located on submuco-
sal glands, epithelial cells, and arterioles. In short-term ex-
plant culture, VIP stimulated lactoferrin release from serous
cells but did not stimulate [3Hjglucosamine-labeled respiratory
glycoconjugate secretion. Methacholine was more potent than
VIP, and methacholine stimulated both lactoferrin and respira-
tory glycoconjugate release. The addition of VIP plus metha-
choline to explants resulted in additive increases in lactoferrin
release. Based upon the autoradiographic distribution of 125I.
VIP binding sites and the effects on explants, VIP derived
from parasympathetic nerve fibers may function in the regula-
tion of serous cell secretion in human nasal mucosa. VIP may
also participate in the regulation of vasomotor tone. (J. Clin.
Invest. 1990. 86:825-831.) Key words: respiratory glycoconju-
gates * mucus * lactoferrin * parasympathetic nervous system
Introduction
Vasoactive intestinal peptide (VIP;' 28 amino acid residues; 1)
is a neurotransmitter in postganglionic parasympathetic
neurons. Preganglionic parasympathetic nerves of the nasal
mucosa originate in the superior salivatory nucleus of the sev-
enth cranial nerve, pass through the Vidian nerve, and synapse
with postganglionic cell bodies in the sphenopalatine ganglion
(2-4). Postganglionic cholinergic neurons contain VIP, pep-
tide with histidine at the NH2 terminus and methionine at the
COOH terminus (PHM), and both choline acetyl transferase
and acetylcholinesterase, which indicate the presence of ace-
tylcholine (5-7). The neurons enter the mucosa via the poste-
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rior nasal nerves and innervate submucosal glands, arterioles,
and venules (3, 4, 7). Stimulation of parasympathetic neurons
leads to the release of acetylcholine, which acts upon musca-
rinic receptors on submucosal glands (8) and possibly vessels
(9, 10).
In humans, stimulation of submucosal glands by exoge-
nous methacholine (8) or central reflexes (1 1) leads to secre-
tion of such mucous cell products as mucous glycoconjugates,
and serous cell products such as lactoferrin, lysozyme, secre-
tory component, and secretory IgA (8, 11-13). Stimulation of
vessels by either cholinergic agonists or central parasympa-
thetic reflexes has been suggested to cause vasodilation (9, 10,
14, 15) and may contribute to the secretion ofplasma products
such as albumin and IgG. Parasympathetic efferent reflexes
may be initiated by afferent sensory nerve stimulation (1 1, 13),
or by "short circuit" stimulation of postganglionic parasympa-
thetic cell bodies by nociceptive, substance P-containing tri-
geminal neurons (16). In addition, electrical stimulation ofthe
sphenopalatine ganglion leads to atropine inhibitable nasal se-
cretion and atropine-resistant vasodilation (3).
Since VIP is released along with acetylcholine by parasym-
pathetic nerves, VIP may play an important role in regulating
nasal responses. However, there is little understanding of the
functions of VIP in the nasal mucosa. Therefore, the concen-
tration of VIP in human nasal mucosa was measured by RIA,
the locations of VIP-immunoreactive nerve fibers were deter-
mined by immunohistochemistry, the distribution of '251I-VIP
binding sites was determined by autoradiography, and the ef-
fects on the secretion ofmucous and serous cell products from
submucosal glands were determined by exposing human nasal
mucosal fragments to VIP in short term explant culture. Based
upon this integrated approach, inferences were made about the
role of VIP in the regulation of vascular and glandular re-
sponses of human nasal mucosa.
Methods
Tissue handling. Human inferior turbinates were obtained at the time
of surgery from 35 patients with nasal obstructive syndromes. No
patient had had a recent infection. At the time of surgery, 2% tetracaine
HCl and 0.25% phenylephrine HCl were applied topically on nasal
packs. The turbinates were injected with 2-4 ml of 1% lidocaine with
1:100,000 epinephrine. An incision was made from the lateral wall of
the inferior turbinate at the level of the infundibulum through the
inferior conchal bone, and then inferiorly along the medial aspect of
that bone. The medial flap of turbinate that remained was wrapped
superiorly and laterally to close the wound. Within 20 min of surgical
excision, the nasal mucosa was dissected from the inferior conchal
bone. Mucosal specimens for autoradiography were frozen in 2-
methyl-butane on dry ice for 20 s, then stored at -700C. Specimens for
explant culture were placed in L15 media (Biofluids, Rockville, MD)
supplemented with 100 ,ug/ml penicillin, 100 ;g/ml streptomycin, and
0.5 gg/ml amphotericin for transport to the laboratory.
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Tissuefixation. Fresh tissues for immunohistological examination
were microwave fixed. Individual 5 X 2 mm fragments of tissue were
placed in plastic scintillation vials (Kimble, Toledo, Ohio) with 10 ml
of 1.5% paraformaldhyde and 0.05% glutaraldehyde in pH 7.4, 50 mM
sodium phosphate, 0.1 M NaCl (PBS) at room temperature and mi-
crowaved (400 W, Sharp Instruments, Mahwah, NJ) for 5 s (17). The
temperature ofthe solution was raised to 45±50C. After fixation, sam-
ples were stored at 40C before being embedded in paraffin (American
Histolabs, Gaithersburg, MD).
Turbinate extract preparation for RIA. Frozen turbinate tissue
from single individuals was weighed (wet weight) and the tissue finely
dissected with razor blades. Three extract procedures were conttasted.
(a) Boiling 0.1 N acetic acid in distilled water was added (20 id/mg
tissue) and boiled for 30 min (adapted from reference 18). During these
30 min, the preparation was homogenized in a ground glass tissue
homogenizer, and sonicated at three intervals (Heat Systems-Ultra-
sonics, Inc., Plainview, NY) for 30 s each at a setting of 6. The suspen-
sion was centrifuged (1,700 g, 30 min, 40C) and the supernatant was
lyophilized.
(b) A solution of cold 50% ethanol, 50% 0.1 N acetic acid, 0.02%
sodium bisulfite in distilled water was added at 20 Ml/mg tissue, and
chilled at 40C for 20 min (adapted from references 19 and 20). During
this period, the mixture sonicated three times for 30 s each on ice. The
tubes were centrifuged and the supernatant was lyophilized.
(c) 2 ml of acetone at 40C were added to 100-300 mg of turbinate
tissue and sonicated as above (adapted from reference 21). After cen-
trifugation, the supernatant was dried by Speed-Vac (Savant Indus-
tries, Hicksville, NY).
The powdered extracts were resuspended in RIA buffer (0.1% BSA,
pH 7.4, 0.1 M sodium phosphate, 0.05 M NaCl, 0.01% NaN3, 0.01%
Tween-80) so that powdered extract equivalent to 10 mg of original
tissue mass was suspended in 100 Al of RIA buffer.
RIA. RIA reagents were purchased from Peninsula Laboratories
(Belmont, CA) and included 3,326 g/mol VIP, 700 Ci/mmol '25I-tyr-
VIP, polyclonal rabbit antiserum to VIP, goat anti-rabbit gamma glob-
ulin serum, and normal rabbit serum. Standard peptide solutions were
prepared for the range from 0.15 to 77.0 fmol per tube (0.5-256 pg per
tube). As a control, samples of ethanol-acetic acid extracts of human
nasal mucosa equivalent to 5 mg of tissue were also added to standard
amounts of VIP to determine if the addition of tissue extracts affected
the accuracy of the RIA.
Turbinate extracts were diluted and aliquotted to give extracts
equal to 10, 3, and I mg of turbinate tissue per tube. Rabbit anti-VIP
serum was added. After overnight incubation at 4°C, 1251-VIP was
added. After a second overnight incubation at 4°C, polyclonal goat
anti-rabbit gamma globulin and nonimmune rabbit serum were added
for 2 h at room temperature. RIA buffer was added, the tubes centri-
fuged at 1,700 g for 40 min, and the supernatants aspirated. The pellets
were counted in a gamma scintillation counter (Beckman Instruments,
Irvine, CA) and the percentage of bound to total counts (B/BO%) was
determined.
The linear portion of the standard curve was analyzed by linear
regression and the yield of VIP per tube was interpolated. The femto-
moles of VIP per tube and picomoles per gram turbinate tissue were
calculated. The mean±SEM picomoles per gram turbinate tissue for
each extraction method was determined.
HPLC. Nasal tissue was extracted in ethanol-acetic acid, lyophi-
lized, and reconstituted in eluent A (0.12% trifluoroacetic acid; Sigma
Chemical Co., St. Louis, MO). After 30 min, nonsoluble material was
removed by centrifugation. An 1 50-IA aliquot was applied to a high
performance liquid chromatogram (1 14M pumps, 421 controller, and
164 detector; Beckman Instruments, Inc., Fullerton, CA) using a C- 18
reverse-phase column (ODS Ultrasphere, 4.6 X 25 cm, 5 Jim pore size,
Beckman Instruments, Inc.). Samples were eluted 5 min after injection
using 45-min runs and a linear gradient of 0-90% eluent B (0.12%
trifluoroacetic acid in acetonitrile) in eluent A (22). Synthetic VIP
(Peninsula Laboratories) was used to standardize the column. Frac-
tions were collected at 1-min intervals, frozen, lyophilized, and recon-
stituted in RIA buffer. The VIP content of each fraction was deter-
mined by RIA.
Indirect immunohistochemistry. 6-Mtm-thick paraffin sections were
sequentially placed in xylene, graded alcohols, distilled water, PBS,
and PBS with 1% nonimmune goat serum (11, 13). Sections were
incubated with rabbit antisera (1:1,000) to VIP (Peninsula Laborato-
ries) or with nonimmune rabbit serum for 18 or 44 h at 4VC. The slides
were washed in PBS, reblocked with 1% nonimmune goat serum in
PBS for 3 min at room temperature, and then 1:40 colloidal gold-la-
beled goat anti-rabbit gamma globulin (Auroprobe; Janssen Pharma-
ceuticals Piscataway, NJ) was added for 60 min at room temperature.
After being washed three times in PBS for 5 min each and three times
in distilled water for 3 min each at room temperature, silver enhancing
solution (IntenSE; Janssen Pharmaceuticals) was added and the devel-
opment of the stained structures was monitored by light microscopy.
The slides were washed in distilled water, dehydrated in graded alco-
hols, and coverslips applied with Permount (Sigma Chemical Co.).
Autoradiography. Frozen sections of tissue were warmed to room
temperature, incubated in pH 7.4, 50 mM Tris, 3 mM MgCl2 for 10
min at 250C, then incubated with 1 nM 251I-VIP in pH 7.4, 50 mM
Tris, 5 mM MgCI2, 2% polypep (Sigma Chemical Co.), 1 MM thior-
phan, 1 MM phosphoramidon, 40 mg/liter bacitracin, 5 mg/liter chy-
mostatin, and 4 mg/liter leupeptin for 3 h at 37°C (adapted from
reference 23). Nonspecific binding was determined by adding 1 JAM
VIP to the incubation mixture. After incubation the slides were washed
twice in pH 7.4, 50 mM Tris for 5 min each at 4°C. The slides were
dried with a stream of cold dry air.
Nuclear track emulsion (NTB-2; Eastman Kodak Co., Rochester,
NY) was melted in the dark for 4 h at 45°C and then mixed with 1%
glycerol in water. In a darkroom, slides were dipped in emulsion, the
backs of the slides wiped clean, and the slides placed vertically for 2 h
to allow the emulsion to run off in an even fashion and dry (24).
Coated slides were placed in plastic boxes with hygroscopic calcium
sulfate (W. A. Hammond Drieite Co., Xenia, OH) and stored at
-200C.
Slides were removed at intervals and warmed to room temperature
in the dark. They were developed in D- 19 developer (Eastman Kodak
Co.) for 2 min at 220C, washed in water for 30 s, fixed in Kodak fixer
for 4 min, and finally washed in water for 15 min.
Human nasal mucosal explant culture. To quantify the release of
secretory cell products in response to VIP, fresh human nasal mucosa
was cut into 3 X 3 mm fragments (25, 26). Pairs of fragments were
placed on gelfoam in petri dishes, and cultured in 2 ml CMRL 1066
containing 100 Mg/ml penicillin, 100 Mg/ml streptomycin, 0.5 Ag/ml
amphotericin (Gibco Laboratories, Grand Island, NY), and 1 MCi/ml
[3Hlglucosamine (New England Nuclear, Boston, MA). The [3HJglu-
cosamine becomes incorporated into newly synthesized respiratory
glycoconjugates (25, 26). After 24 h, the media was changed and 400
KIU/ml aprotinin (Sigma Chemical Co.) was added to the mixture.
After an additional 24 h, fresh media with aprotinin was added for 4 h
(period I [Pl]). The culture supernatant from this baseline period was
collected and then replenished for I hour (period 2 [P2]) by aprotinin
containing media with 0.1, 1, and 5 MM VIP (Peninsula Laboratories),
1, 10, and 100MM methacholine (Sigma Chemical Co.); combinations
ofVIP and methacholine; or media (control plates). Supernatants from
P1 and P2 were used for quantitation of respiratory glycoconjugates
and lactoferrin.
Respiratory glycoconjugate release was quantified by precipitation
of [3H]glycoconjugates in 10% TCA and 1% phosphotungstic acid
(TCA/PTA) at 5°C overnight. The precipitates were pelleted by cen-
trifugation (1,200 g for 10 min), washed twice with TCA/PTA and
hydrolyzed in 0.1 M NaOH. Aliquots of the resuspended precipitates
were used for scintillation counting. The ratios of disintegrations per
minute for P2 to P1 (secretory index) were calculated for each treat-
ment. The secretory indices were compared with control cultures, and
the percent change from control (mean±SEM) was calculated. Results
were statistically compared to controls using the paired t test.
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Lactoferrin ELISA. Quantitation of lactoferrin release into the
culture media from P1 and P2 for each treatment was performed by
using a noncompetitive ELISA (1 1). Microtiter plates were coated with
50 gl of rabbit anti-human lactoferrin (Dako Corp., Santa Barbara,
CA) diluted 1:1,000 in 0.1 M carbonate buffer, pH 9.6, and incubated
at 40C overnight. The wells were washed with 4 vol of a buffer (PT)
consisting ofPBS, pH 7.4, with 0.05% Tween 80 (Fisher Scientific, Fair
Lawn, NJ). After blocking nonspecific binding sites with 200 yd of 1%
goat serum (Gibco Laboratories) in PT for 30 min at room tempera-
ture, 50 ,d of media or standard (diluted in PT) was added to each well
and incubated at 370C for 90 min. Then 50 ,d of goat anti-human
lactoferrin conjugated to horseradish peroxidase (Organon Teknika-
Cappel, West Chester, PA) was added and incubated at 370C for 90
min. The color reaction was developed with an o-phenylenediamine
dihydrochloride substrate (Sigma Chemical Co.), and then the optical
densities of the plates were read at 490 nm on an ELISA reader (Dy-
natech Laboratories, Alexandria, VA). The ratios of optical densities
from the supernatants collected during P2 to that for P1 (secretory
index) were calculated for each treatment as above, and the mean
(±SEM) percent change in secretory indices from control values was
calculated. The secretory indices for each treatment were compared
with the control values by paired t test.
Results
RIA. The sigmoid standard curve was linear between 1.2 and
38.5 fmol (4 and 128 pg) per tube. Using linear regression, the







were between 0.96 and 0.99. The sensitivity (concentration at
B/Bo = 50%) ofthe assay was 5.83±0.62 fmol per tube (n = 5).
The addition of ethanol-acetic acid extract equivalent to 5 mg
of nasal mucosa did not affect the shape of the standard curve
or the slope ofthe linear portion, even though the addition did
shift the curve slightly to the right. The VIP content ofhuman
turbinate nasal mucosa was estimated by interpolation of
B/Bo% values from the linear portion of the standard curve.
Samples extracted with boiling acetic acid yielded
2.84±0.47 pmol per g wet weight tissue (n = 8). Content
ranged from 1.07 to 4.61. Samples extracted with ethanol-ace-
tic acid yielded 2.84±0.38 pmol per g (n = 17 patients) with a
range from 0.70 to 5.80. Samples extracted with acetone
yielded 0.80±0.10 pmol per g (n = 4), with a range between
0.23 and 1.03.
HPLC. Synthetic VIP (25 ,ug) eluted from the HPLC col-
umn with a single, narrow peak at 25.96 min. Using the RIA,
VIP eluted only in fractions collected at 25 and 26 min. When
turbinate tissue was eluted from the HPLC column, VIP im-
munoreactive material was collected only at 25 and 26 min.
All other fractions for both the standards and tissue contained
no immunoreactive VIP.
Indirect immunohistochemistry. Human inferior turbinate
nasal mucosa is covered by ciliated pseudostratified columnar
respiratory epithelium (Fig. 1). Beneath the basement mem-




















Figure 1. VIP immunoreactive nerve fibers in human nasal mucosa. (a) VIP nerve fibers (arrowheads) are seen in a nerve bundle (NB) and in
the wall of a small venule (V). Hematoxylin counterstain. (b) A VIP nerve fiber (arrowheads) is seen innervating mucous cells (M) of a submu-
cosal gland acinus. Nuclear fast red counterstain. (c) VIP nerve fibers are seen innervating serous cells (S) and mucous cells (M) of a submuco-
sal gland. Nuclear fast red counterstain. (d) Negative control. VIP antiserum adsorbed with excess VIP did not identify VIP immunoreactive
structures in these serous (S) and mucous (M) acinii or venule. Nuclear fast red counterstain. Bars, 25 Am.
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zone are interspersed tubuloacinar seromucous submucosal
glands and their ducts. In the connective tissue between sub-
mucosal glands are large venous sinusoids. Coiled arterioles
and nerve bundles are located deeper in the mucosa.
VIP-immunoreactive material was identified readily in tis-
sue fixed by microwave irradiation. Microwave fixation al-
lowed rapid tissue processing and excellent preservation of
tissue histology, and improved the identification of immuno-
reactive nerve fibers when compared with other fixation tech-
niques ( 17). This may reflect the rapidity of tissue fixation by
microwave irradiation.
Staining sections with nuclear fast red (Sigma Chemical
Co.) allowed tissue definition which did not obscure nerve
fibers. Other stains obscured detection ofimmunoreactive VIP
nerves which could otherwise be seen in unstained sections.
VIP immunoreactive nerve fibers were most frequently
encountered in submucosal glands (Fig. 1). The fibers were
often in direct contact with acinar cells. There was apparent
contact with both serous and mucous cells, and with the myo-
epithelial cells that surround each acinus. VIP fibers were seen
in nerve bundles. Some VIP nerve fibers were also detected in
the walls of arterial and venous vessels. More fibers were seen
in glands than vessels. No fibers were found in the epithelium.
Autoradiography. '25I-VIP binding sites on the epithelium
and submucosal glands of human nasal mucosa were detected
as deposits of silver grains using darkfield microscopy (Fig. 2).
It was not possible to determine if 1251I-VIP bound preferen-
tially to specific subsets of cells such as goblet cells, serous cells,
or mucous cells since the use of mucous cell-specific stains












silver grains. There also appeared to be binding of '251-VIP to
the vascular smooth muscle of arterioles (Fig. 3). It was not
possible to differentiate between smooth muscle or endothelial
binding of 1251I-VIP due to the scatter of radiation from 1251
decay. However, venous sinusoids bound very little '25I-VIP,
suggesting that the endothelium of these thin walled vessels
had very few or no VIP binding sites. The addition of excess
VIP ablated binding to epithelium, glands, and arterioles (Figs.
2fand 3 d).
Human nasal mucosal explant culture. Methacholine (MC)
between 1 and 100 ,uM induced dose dependant secretion of
lactoferrin and [3H]glucosamine labeled respiratory glycocon-
jugates (Table I). Release oflactoferrin was significantly stimu-
lated at 1 gM MC whereas glycoconjugate release was un-
changed from control, indicating that either lactoferrin con-
taining serous cells responded to lower concentrations of
methacholine than glycoconjugate containing cells, or that
changes in lactoferrin secretion were more readily detected
than changes in glycoconjugate secretion. VIP in doses of
0.1-5 IgM induced significant lactoferrin secretion, but did not
affect glycoconjugate secretion. At concentrations of 1 uM,
methacholine was more potent than VIP at inducing lactofer-
rin secretion.
Since VIP and acetylcholine may be simultaneously re-
leased from parasympathetic nerves, the effects of combina-
tions of methacholine and VIP were studied. The addition of
VIP to 1 uM methacholine did not stimulate glycoconjugate
release or augment the release of lactoferrin. The addition of
VIP to 10 1AM methacholine did not affect glycoconjugate re-
lease. Lactoferrin release was increased in additive but not
Figure 2. '25I-VIP binding sites in human nasal
mucosa. (A) Brightfield image of epithelium (e)
and lamina propria. Submucosal glands (g) and
sinusoids (s) are seen. (B) Darkfield image of the
same field as A, indicating '25I-VIP binding to
the epithelium (e) and submucosal glands (g).
Sinusoids (s) did not demonstrate binding. (C)
Brightfield image of a dense collection of sub-
mucosal glands (g) and adjacent venous sinu-
soids (s). (D) Darkfield image of the same field
as (C) showing 1251-VIP binding to submucosal
glands (g) but not sinusoids (s). (E) Brightfield
image from a consecutively cut tissue section
showing vessels (v) and submucosal glands (g)
on a slide treated with 1 AM VIP. (F) Darkfield
image of the same field as E, showing that the
addition of excess VIP ablated the binding of
'251-VIP. Toluidine blue counterstaining. Bars,
50 Am.
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Figure 3. '25I-VIP binding sites in human nasal mucosa. (A) Brightfield image of an arteriole (a), submucosal glands (g), and sinusoids (s). (B)
Darkfield image of the same field as A, showing '25I-VIP binding to the arteriole (a) and glands (g), but no binding to the venous structures (s).
(C) Brightfield image showing several vessels with vascular smooth muscle in their walls (arrowheads indicate representative areas). Several ar-
terioles (a), thin muscular veins, and venous sinusoids (s) are shown. (D) Darkfield image of the same field as C shows silver grains over the
areas of vascular smooth muscle (arrowheads). Areas without smooth muscle did not appear to demonstrate binding. Toluidine blue counter-
staining. Bars, 50,gm.
synergistic fashion by 5 AM VIP plus 10 AM methacholine.
These results indicate that VIP stimulated serous cell secre-
tion, but that VIP was less potent than methacholine. VIP did
not potentiate the effects of methacholine on secretion from
either serous cells or [3H]glucosamine-labeled respiratory gly-
coconjugate-containing cells.
Table I. Effects of VIP and Methacholine on the Release
ofLactoferrin and [3H]Glucosamine-labeled Respiratory
Glycoconjugates from Human Nasal Mucosa in Explant Culture
VIP MC n Lactoferrin Glycoconjugates
AM MM % Change P % Change P
0 100 16 460±96 <0.001 31.8±7.4 <0.001
0 10 7 563±177 <0.02 17.0±12.0 NS
0 1 6 124±24 <0.005 -0.6±2.6 NS
5 0 14 132±37 <0.01 3.9±5.1 NS
1 0 9 114±29 <0.01 -2.2±3.8 NS
0.1 0 9 90±35 <0.05 8.9±12.1 NS
5 10 9 759±320 <0.05 16.6±9.9 NS
1 10 7 574±203 <0.02 13.0±5.1 <0.02
0.1 10 6 411±125 <0.01 16.6±6.9 <0.01
Mean±SEM; unpaired t test.
Discussion
VIP was present in human nasal mucosa. The concentration of
acid ethanol extractable VIP (2.84±0.38 pmol per g tissue) was
slightly less than the concentration of neuropeptides which we
have measured previously. Neuropeptide Y (NPY), a neuro-
transmitter of sympathetic neurons in human nasal mucosa
(28, 29), has a concentration of 3.13±0.79 pmol per g tissue.
The concentration of VIP was greater than the concentration
of calcitonin gene-related peptide (CGRP; 0.54±0.08 pmol
per g), a neurotransmitter of trigeminal, nociceptive, type C
sensory neurons (16, 30-32). The relative enrichment of VIP
reflects the abundant supply of parasympathetic, cholinergic
nerves to the nasal mucosa.
VIP-immunoreactive nerve fibers were located predomi-
nantly around submucosal glands. Individual fibers were also
seen in the walls of venules and arterioles. The distribution of
VIP contrasts with that of CGRP (32) from sensory neurons,
and NPY (29) of sympathetic neurons. CGRP fibers and NPY
fibers densely innervate arterial vessels, whereas individual
CGRP fibers and NPY fibers were present in the walls of
venous vessels and occasionally in submucosal gland acini.
CGRP fibers were also found in the nasal epithelium. VIP
fibers in the trachea and bronchi have been found around
blood vessels, in smooth muscle bundles, submucosal glands,
and near the epithelium (33, 34).






'25l-VIP binding sites were found on submucosal glands,
epithelium, and in the walls of arterioles and veins in human
nasal mucosa. This was similar to the distribution of VIP
found in the lower respiratory tract, where VIP receptors have
been demonstrated on tracheobronchial epithelium, submu-
cosal glands, and alveolar walls (23). The highest density of
VIP receptors were found on pulmonary vascular smooth
muscle, and bronchial smooth muscle of trachea and bronchi
(35, 36).
VIP-containing neurons also contain a closely related pep-
tide: PHM (37, 38). Although VIP, PHM, and acetylcholine
are all present in the peripheral neurosecretory varicosities of
postganglionic parasympathetic neurons (39), the amounts of
each released during neural transmission appears to depend
upon the nerve impulse frequency (39). At low rates, acetyl-
choline is selectively released. At high rates, acetylcholine to-
gether with VIP and PHM are released. VIP may augment the
postsynaptic acetylcholine-induced secretory response in
glands (e.g., cat salivary glands, reference 40), but may also
have presynaptic inhibitory effects which could act to limit
neuropeptide release. This mechanism would conserve the
amount ofstored peptides since there are no re-uptake mecha-
nisms, and VIP and PHM can only be resupplied by axonal
transport from the cell body (37, 39). This principle may be
very important in understanding the physiology ofparasympa-
thetic neurons.
VIP stimulates many aspects of exocrine function and in-
creases the content of chloride in intestinal and bronchial se-
cretions, and pancreatic secretion of bicarbonate, water, and
macromolecules (33). In respiratory tissues, however, the ef-
fects of VIP on glands have been inconsistent. Tracheal tissues
from ferret (41, 42) and dog (43) release modest amounts of
respiratory glycoconjugates ("mucus") in response to VIP.
VIP induces serous cell exocytosis from ferret tracheal explants
(42). Feline tracheal explants do not respond to VIP (44).
However, isolated feline submucosal glands do respond (44),
and VIP augments the secretory responses of methacholine
(44) and other secretagogues (45). In humans, incubation of
tracheal explants with 0.2-2,000 nM VIP inhibited [3H]glyco-
conjugate release from normal subjects, but had no effect upon
explants from subjects with chronic bronchitis (46).
The present explant results indicate that VIP stimulated
lactoferrin secretion from serous cells. VIP was less potent
than methacholine and did not significantly augment musca-
rinic receptor-mediated stimulation of lactoferrin secretion.
VIP did not stimulate [3H]glucosamine-labeled respiratory
glycoconjugate release and did not affect methacholine-in-
duced secretion. The release of lactoferrin was much more
responsive than [3H]glycoconjugate release. Either serous cells
were more sensitive to methacholine than glycoconjugate-
containing cells, or lactoferrin was a more sensitive marker of
submucosal gland secretion than glycoconjugates. Therefore,
VIP augments the effects ofcholinergic stimulation by causing
selective enrichment ofserous cell products in nasal secretions.
The activation of VIP receptors on serous cells of submucosal
glands represents an additional component which must be
considered when studying parasympathetic reflexes in human
upper respiratory tract (1 1).
'25I-VIP binding sites were also found on vessels. VIP in-
duces dilation of human submandibular arteries in vitro (15)
and feline nasal vessels in vivo (47, 48). VIP augments the
cutaneous plasma extravasation that can be induced by sub-
stance P (49).
Alterations of VIP metabolism may contribute to several
clinical syndromes. Increased VIP immunohistochemical
staining in nasal mucosa has been reported in patients with an
allergic diathesis and symptoms of paroxysmal nasal obstruc-
tion (50). Increased release ofVIP and other neurotransmitters
by the parasympathetic route could contribute to the chronic
vascular congestion and hypersecretion characteristic of some
obstructive nasal syndromes. In contrast, VIP-immunoreac-
tive nerve fibers may be absent from bronchial walls in pa-
tients who die of status asthmaticus (5 1). These asthmatic pa-
tients were also reported to have increased relative densities of
substance P-immunoreactive nerve fibers in their bronchial
mucosa (52). These findings suggest that abnormalities of
neuropeptide containing nerves could contribute to the patho-
genesis of respiratory diseases. Prospective studies with care-
fully defined patient groups and appropriate controls are re-
quired to implicate neuropeptides in specific disease states.
These observations indicate that VIP is present in human
nasal mucosa and that VIP-immunoreactive neurons inner-
vate submucosal glands and vessels. VIP binding sites are pres-
ent on the epithelium, submucosal glands, and the walls of
arterioles. VIP stimulated lactoferrin release from human
nasal mucosal fragments. Since serous cell products include
specific and nonspecific antimicrobial factors, this selective
response could be an important regulator of mucosal host de-
fense mechanisms.
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